Shrivastava Trilok, Van Rhee Frits, Al Hadidi Samer
Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Onco Targets Ther. 2023 Jun 20;16:441-464. doi: 10.2147/OTT.S370880. eCollection 2023.
Relapsed/refractory multiple myeloma remains a challenging disease necessitating the development of more effective treatment options. In the past decade, myeloma therapies have made significant advancements with the introduction of new treatment modalities. One of the new major targets for these novel therapeutics has been B-cell maturation antigen (BCMA), which is expressed on mature B-lymphocytes and plasma cells. There are three main categories of BCMA-targeted therapies currently available, including bispecific antibodies (BsAbs), antibody drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies. In this review, we discuss the existing BCMA-targeted therapies and provide insights into currently available treatment and future developments, with a particular focus on clinical efficacy and common drug-related adverse events.
复发/难治性多发性骨髓瘤仍然是一种具有挑战性的疾病，需要开发更有效的治疗方案。在过去十年中，随着新治疗方式的引入，骨髓瘤治疗取得了重大进展。这些新型疗法的一个主要新靶点是B细胞成熟抗原（BCMA），它在成熟B淋巴细胞和浆细胞上表达。目前有三类主要的靶向BCMA疗法，包括双特异性抗体（BsAbs）、抗体药物偶联物（ADCs）和嵌合抗原受体（CAR）T细胞疗法。在本综述中，我们讨论了现有的靶向BCMA疗法，并深入探讨了当前可用的治疗方法和未来发展，特别关注临床疗效和常见的药物相关不良事件。
